Evidence map›Paper›PMID 32209647›Full record

Trial reportDiabetes care2020

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).

Wendy S Lane, Elena Favaro, Naveen Rathor, Hak C Jang, Maiken I S Kjærsgaard, Alejandra Oviedo, Ludger Rose, Peter Senior, Giorgio Sesti, Alfonso Soto Gonzalez and 1 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03268005. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03268005 phase3completed

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset® 9)

Ran2017Enrolled1,264Registered outcomes52Posted comparisons1ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsFaster-acting insulin aspart, Insulin Aspart, insulin degludec, Metformin
Open the trial in the graph
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 9 countries.

Wendy S LaneMountain Diabetes and Endocrine Centre, Asheville, NC mountaindiabetes@msn.com.ORCID 0000-0002-4317-9106
Elena FavaroNovo Nordisk A/S, Søborg, Denmark.
Naveen RathorNovo Nordisk A/S, Søborg, Denmark.
Hak C JangDepartment of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, South Korea.ORCID 0000-0002-4188-6536
Maiken I S KjærsgaardNovo Nordisk A/S, Aalborg, Denmark.
Alejandra OviedoSantojanni Hospital and CENUDIAB, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina.
Ludger RoseInstitute of Diabetes Research, Münster, Germany.
Peter SeniorDivision of Endocrinology and Metabolism, University of Alberta, Edmonton, Alberta, Canada.
Giorgio SestiDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.ORCID 0000-0002-1618-7688
Alfonso Soto GonzalezService of Endocrinology and Nutrition, University Hospital of A Coruña, La Coruña, Spain.
Edward FranekMossakowski Clinical Research Center, Polish Academy of Sciences, and Department of Endocrinology and Diabetology, Central Clinical Hospital of the MSWiA, Warsaw, Poland.
Novo Nordisk (Denmark) · DKCentral Clinical Hospital · PLGerman Center for Diabetes Research · DEHospital Donación Francisco Santojanni · ARMountain Diabetes and Endocrine Center · USSapienza University of Rome · ITSeoul National University Bundang Hospital · KRUniversidade da Coruña · ESUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp), both with insulin degludec with or without metformin, in adults with type 2 diabetes not optimally controlled with a basal-bolus regimen. RESEARCH DESIGN AND

methodsThis multicenter, double-blind, treat-to-target trial randomized participants to faster aspart (

resultsNoninferiority for the change from baseline in HbA

conclusionsIn combination with insulin degludec, faster aspart provided effective overall glycemic control, superior PPG control, and a lower rate of severe or BG-confirmed hypoglycemia versus IAsp in adults with type 2 diabetes not optimally controlled with a basal-bolus regimen.

Indexed as

Insulin AspartInsulin, Long-ActingMetforminAgedBlood GlucoseDiabetes Mellitus, Type 2Double-Blind MethodDrug CombinationsDrug Therapy, CombinationFemaleGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsMaleMealsBlood GlucoseDrug CombinationsGlycated HemoglobinHypoglycemic AgentsInsulin Aspartinsulin degludecinsulin degludec, insulin aspart drug combinationInsulin, Long-ActingMetformin

Identifiers

PMID32209647
PMCPMC7372057
OpenAlexW3014035905

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.